Solutions: Extend trial to 6 months before concluding inefficacy (some benefits take longer), increase dosing within safe ranges if using lower end, switch peptides (try Cerebrolysin if using BPC-157, or vice versa), add comprehensive eye exam to rule out progression versus peptide failure, consider peptides preventing worsening rather than producing improvement, discontinue if truly no benefit after 6 months rigorous trial
FOXO signaling appears to have the potential to increase autophagy and proteasomal activity in the heart, thus speeding up the clearing of damaged cells
a , Schematic of senolytic experiment performed with ferroptosis inducer in SK-MEL103 and IMR90 cells
Histone deacetylase HDA-1 modulates mitochondrial stress response and longevity
This dual mechanism, reduced intake plus increased expenditure, explains why the Phase 2 data showed such dramatically higher weight loss percentages than any dual agonist trial
Ignoring reconstitution volume in dose calculations